XCMR has received a $99,771 Phase 1 SBIR award from the Environmental Protection Agency (EPA) to support its development of Far UV-C technology for decontamination and infection control. This award will fund a 6-month project aimed at advancing XCMR’s human-safe Far UV-C technology, which is designed to inactivate airborne pathogens continuously, providing enhanced protection for individuals in high-risk environments.
This Phase 1 EPA award underscores XCMR’s commitment to creating Far UV-C solutions that safeguard against airborne pathogens. Far UV-C technology holds the potential to inactivate harmful viruses and bacteria in real-time, making it a game-changer for healthcare facilities, public spaces, and workplaces.
The EPA SBIR program is designed to foster innovation and support small businesses that are developing technologies with environmental and public health impacts. XCMR’s project aligns perfectly with the EPA’s mission, providing a sustainable and effective approach to pathogen inactivation.
This funding will enable XCMR to demonstrate proof of concept for its human-safe Far UV-C microplasma lamps, setting the stage for further development and scaling. Success in this Phase 1 project could lead to additional support from the EPA and other agencies, allowing XCMR to bring its life-saving technology to a broader market.
XCMR’s receipt of the EPA Phase 1 SBIR award highlights its pioneering role in developing next-generation infection control technologies. With this funding, XCMR is well-positioned to advance its Far UV-C research and provide real-world solutions that enhance public health and safety.
